EIF4E抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using EIF4E mouse mAb against Hela (1), HEK293 (2) and K562 (3) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of GC-7901 cells using EIF4E mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using EIF4E mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer (left) and submaxillary tumor (right) using EIF4E mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer (left) and prostate cancer (right) using EIF4E mouse mAb with DAB staining.    

  
  

The eukaryotic translation initiation factor 4E (eIF4E) plays a critical role in cap-dependent mRNA translation initiation by binding to the 5' cap structure of mRNAs. It is a key regulator of protein synthesis, influencing cellular processes like proliferation, survival, and angiogenesis. Dysregulation of eIF4E is implicated in cancer, where its overexpression enhances the translation of oncogenic mRNAs (e.g., cyclins, VEGF), promoting tumor progression and therapy resistance.

eIF4E antibodies are essential tools in studying its expression, localization, and activity in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to quantify eIF4E levels in tissues or cell lines. Researchers also employ them to investigate eIF4E's interaction with binding partners (e.g., eIF4G, 4E-BPs) or its phosphorylation status, which modulates its function.

In cancer research, eIF4E antibodies help assess its role as a biomarker or therapeutic target. For instance, targeting eIF4E with inhibitors or siRNA often requires antibody-based validation of knockdown efficiency. Commercial eIF4E antibodies are typically raised against specific epitopes (human or murine) and validated for cross-reactivity. Understanding eIF4E's regulatory pathways (e.g., mTOR signaling) using these antibodies has advanced strategies to disrupt oncogenic translation in precision medicine.